Sodium MR Imaging Detection of Mild Alzheimer Disease: Preliminary Study

References

1. ↵
   Kasper DL, Harrison TR. Harrison's Principles of Internal Medicine. New York: McGraw-Hill;2005
2. ↵
   Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007;69:1622–34

   Abstract/FREE Full Text
3. ↵
   Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605–13

   CrossRefPubMedWeb of Science
4. ↵
   Cohen RM. The application of positron-emitting molecular imaging tracers in Alzheimer's disease. Mol Imaging Biol 2007;9:204–16

   CrossRefPubMed
5. ↵
   Ramani A, Jensen JH, Helpern JA. Quantitative MR imaging in Alzheimer disease. Radiology 2006;241:26–44

   CrossRefPubMedWeb of Science
6. ↵
   Seab JP, Jagust WJ, Wong ST, et al. Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med 1988;8:200–08

   CrossRefPubMedWeb of Science
7. ↵
   Jernigan TL, Salmon DP, Butters N, et al. Cerebral structure on MRI, Part II: Specific changes in Alzheimer's and Huntington's diseases. Biol Psychiatry 1991;29:68–81

   PubMedWeb of Science
8. ↵
   Fox NC, Cousens S, Scahill R, et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000;57:339–44

   CrossRefPubMedWeb of Science
9. ↵
   Jack CR Jr, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998;51:993–99

   Abstract/FREE Full Text
10. ↵
    Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003;60:253–60

    Abstract/FREE Full Text
11. ↵
    Klunk WE, Panchalingam K, Moossy J, et al. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 1992;42:1578–85

    Abstract/FREE Full Text
12. ↵
    Jessen F, Traeber F, Freymann K, et al. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006;67:528–30

    Abstract/FREE Full Text
13. ↵
    Falangola MF, Dyakin VV, Lee SP, et al. Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease. NMR Biomed 2007;20:343–51

    CrossRefPubMed
14. ↵
    El Tannir El Tayara N, Delatour B, Le Cudennec C, et al. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2006;22:199–208

    CrossRefPubMed
15. ↵
    Borthakur A, Gur T, Wheaton AJ, et al. In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J Magn Reson Imaging 2006;24:1011–17

    CrossRefPubMed
16. ↵
    Haley AP, Knight-Scott J, Fuchs KL, et al. Shortening of hippocampal spin-spin relaxation time in probable Alzheimer's disease: a 1H magnetic resonance spectroscopy study. Neurosci Lett 2004;362:167–70

    CrossRefPubMed
17. Campeau NG, Petersen RC, Felmlee JP, et al. Hippocampal transverse relaxation times in patients with Alzheimer disease. Radiology 1997;205:197–201

    PubMed
18. ↵
    House MJ, St Pierre TG, Foster JK, et al. Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. AJNR Am J Neuroradiol 2006;27:430–39

    Abstract/FREE Full Text
19. ↵
    Borthakur A, Wang C, Li D, et al. T_1ρ MRI of patients with Alzheimer's disease. Proceedings of the 15th Annual Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine;2007 :3727 .
20. ↵
    Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000;47:93–100

    CrossRefPubMedWeb of Science
21. ↵
    Kabani NJ, Sled JG, Chertkow H. Magnetization transfer ratio in mild cognitive impairment and dementia of Alzheimer's type. Neuroimage 2002;15:604–10

    CrossRefPubMedWeb of Science
22. ↵
    Lin AP, Shic F, Enriquez C, et al. Reduced glutamate neurotransmission in patients with Alzheimer's disease –an in vivo (13)C magnetic resonance spectroscopy study. Magma 2003;16:29–42

    CrossRefPubMed
23. ↵
    Gonzalez RG, Guimaraes AR, Moore GJ, et al. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:46–52

    PubMedWeb of Science
24. ↵
    Higuchi M, Iwata N, Matsuba Y, et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005;8:527–33

    CrossRefPubMedWeb of Science
25. ↵
    Shapiro EM, Borthakur A, Gougoutas A, et al. 23Na MRI accurately measures fixed charge density in articular cartilage. Magn Reson Med 2002;47:284–91

    CrossRefPubMedWeb of Science
26. ↵
    Borthakur A, Mellon E, Niyogi S, et al. Sodium and T1rho MRI for molecular and diagnostic imaging of articular cartilage. NMR Biomed 2006;19:781–821

    CrossRefPubMedWeb of Science
27. ↵
    Jansen MA, Van Emous JG, Nederhoff MG, et al. Assessment of myocardial viability by intracellular 23Na magnetic resonance imaging. Circulation 2004;110:3457–64

    Abstract/FREE Full Text
28. ↵
    Turski PA, Houston LW, Perman WH, et al. Experimental and human brain neoplasms: detection with in vivo sodium MR imaging. Radiology 1987;163:245–49

    PubMed
29. ↵
    Nielles-Vallespin S, Weber MA, Bock M, et al. 3D radial projection technique with ultrashort echo times for sodium MRI: clinical applications in human brain and skeletal muscle. Magn Reson Med 2007;57:74–81

    CrossRefPubMedWeb of Science
30. ↵
    Shimizu T, Naritomi H, Sawada T. Sequential changes on 23Na MRI after cerebral infarction. Neuroradiology 1993;35:416–19

    CrossRefPubMed
31. ↵
    Thulborn KR, Gindin TS, Davis D, et al. Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology 1999;213:156–66

    CrossRefPubMedWeb of Science
32. ↵
    Boada FE, Laverde G, Jungreis C, et al. Loss of cell ion homeostasis and cell viability in the brain: what sodium MRI can tell us. Curr Top Dev Biol 2005;70:77–101

    CrossRefPubMed
33. ↵
    Horn M. 23Na magnetic resonance imaging for the determination of myocardial viability: the status and the challenges. Curr Vasc Pharmacol 2004;2:329–33

    CrossRefPubMed
34. ↵
    Beekly DL, Ramos EM, van Belle G, et al. The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord 2004;18:270–77

    PubMed
35. ↵
    Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210–16

    CrossRefPubMedWeb of Science
36. ↵
    Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24:637–39

    PubMedWeb of Science
37. ↵
    Alecci M, Collins CM, Wilson J, et al. Theoretical and experimental evaluation of detached endcaps for 3 T birdcage coils. Magn Reson Med 2003;49:363–70

    CrossRefPubMed
38. ↵
    Bartzokis G, Mintz J, Marx P, et al. Reliability of in vivo volume measures of hippocampus and other brain structures using MRI. Magn Reson Imaging 1993;11:993–1006

    CrossRefPubMedWeb of Science
39. ↵
    Watson C, Andermann F, Gloor P, et al. Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology 1992;42:1743–50

    Abstract/FREE Full Text
40. ↵
    Jack CR Jr, Petersen RC, O'Brien PC, et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 1992;42:183–88

    Abstract/FREE Full Text
41. ↵
    Siegel GJ. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia: Lippincott-Raven;1999
42. ↵
    Perman WH, Turski PA, Houston LW, et al. Methodology of in vivo human sodium MR imaging at 1.5 T. Radiology 1986;160:811–20

    PubMedWeb of Science
43. ↵
    Reddy R, Bolinger L, Shinnar M, et al. Detection of residual quadrupolar interaction in human skeletal muscle and brain in vivo via multiple quantum filtered sodium NMR spectra. Magn Reson Med 1995;33:134–39

    CrossRefPubMed
44. ↵
    Boada FE, Christensen JD, Huang-Hellinger FR, et al. Quantitative in vivo tissue sodium concentration maps: the effects of biexponential relaxation. Magn Reson Med 1994;32:219–23

    PubMed
45. ↵
    Clayton DB, Lenkinski RE. MR imaging of sodium in the human brain with a fast three-dimensional gradient-recalled-echo sequence at 4 T. Acad Radiol 2003;10:358–65

    CrossRefPubMed
46. ↵
    Rooney WD, Springer CS, Jr. The molecular environment of intracellular sodium: 23Na NMR relaxation. NMR Biomed 1991;4:227–45

    PubMed
47. ↵
    Bansal N, Germann MJ, Seshan V, et al. Thulium 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonate) as a 23Na shift reagent for the in vivo rat liver. Biochemistry 1993;32:5638–43

    CrossRefPubMedWeb of Science
48. ↵
    Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A 1993;90:567–71

    Abstract/FREE Full Text
49. ↵
    Mark RJ, Hensley K, Butterfield DA, et al. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosci 1995;15:6239–49

    Abstract
50. ↵
    Lin SP, Song SK, Miller JP, et al. Direct, longitudinal comparison of (1)H and (23)Na MRI after transient focal cerebral ischemia. Stroke 2001;32:925–32

    Abstract/FREE Full Text
51. ↵
    Kim RJ, Judd RM, Chen EL, et al. Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. Circulation 1999;100:185–92

    Abstract/FREE Full Text
52. ↵
    Alecci M, Romanzetti S, Kaffanke J, et al. Practical design of a 4 Tesla double-tuned RF surface coil for interleaved 1H and 23Na MRI of rat brain. J Magn Reson 2006;181:203–11

    CrossRefPubMed
53. ↵
    Bartha R, Menon RS. Long component time constant of 23Na T*2 relaxation in healthy human brain. Magn Reson Med 2004;52:407–10

    CrossRefPubMed
54. Steidle G, Graf H, Schick F. Sodium 3-D MRI of the human torso using a volume coil. Magn Reson Imaging 2004;22:171–80

    CrossRefPubMedWeb of Science
55. Sandstede JJ, Hillenbrand H, Beer M, et al. Time course of 23Na signal intensity after myocardial infarction in humans. Magn Reson Med 2004;52:545–51

    CrossRefPubMed
56. ↵
    Stobbe R, Beaulieu C. In vivo sodium magnetic resonance imaging of the human brain using soft inversion recovery fluid attenuation. Magn Reson Med 2005;54:1305–10

    CrossRefPubMed
57. ↵
    Reddy R, Insko EK, Leigh JS. Triple quantum sodium imaging of articular cartilage. Magn Reson Med 1997;38:279–84

    CrossRefPubMed
58. Hancu I, Boada FE, Shen GX. Three-dimensional triple-quantum-filtered (23)Na imaging of in vivo human brain. Magn Reson Med 1999;42:1146–54

    CrossRefPubMed
59. ↵
    Borthakur A, Hancu I, Boada FE, et al. In vivo triple quantum filtered twisted projection sodium MRI of human articular cartilage. J Magn Reson 1999;141:286–90

    CrossRefPubMed
60. ↵
    Ouwerkerk R, Bleich KB, Gillen JS, et al. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology 2003;227:529–37

    CrossRefPubMedWeb of Science
61. ↵
    Strange K. Regulation of solute and water balance and cell volume in the central nervous system. J Am Soc Nephrol 1992;3:12–27

    Abstract